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1Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology (NTNU), Trondheim
7030, Norway; 2Department of Oncology, St Olavs University Hospital, Olav Kyrres gt 13, Trondheim 7006, Norway; 3Department of Public Health,
University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK; 4Department of Laboratory Medicine, Children’s and Women’s Health, Faculty of
Medicine, Norwegian University of Science and Technology (NTNU), Trondheim 7030, Norway; 5Department of Clinical Surgery, University of Edinburgh,
Clinical and Surgical Sciences (Surgery), Royal Inf irmary, 51 Little France Crescent, Edinburgh EH16 4SA, UK; 6Department of Oncology (Division of
Palliative Care Medicine), University of Alberta, Edmonton, Alberta, Canada T6G 1Z2; 7Department of Anaesthesiology and Emergency Medicine, St Olav
University Hospital, Trondheim 7006, Norway; 8Department of Circulation and Medical Imaging, Norwegian University of Science and Technology,
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BACKGROUND: Cachexia has major impact on cancer patients’ morbidity and mortality. Future development of cachexia treatment
needs methods for early identification of patients at risk. The aim of the study was to validate nine single-nucleotide polymorphisms
(SNPs) previously associated with cachexia, and to explore 182 other candidate SNPs with the potential to be involved in the
pathophysiology.
METHOD: A total of 1797 cancer patients, classified as either having severe cachexia, mild cachexia or no cachexia, were genotyped.
RESULTS: After allowing for multiple testing, there was no statistically significant association between any of the SNPs analysed and the
cachexia groups. However, consistent with prior reports, two SNPs from the acylpeptide hydrolase (APEH) gene showed suggestive
statistical significance (P¼ 0.02; OR, 0.78).
CONCLUSION: This study failed to detect any significant association between any of the SNPs analysed and cachexia; although two
SNPs from the APEH gene had a trend towards significance. The APEH gene encodes the enzyme APEH, postulated to be important
in the endpoint of the ubiquitin system and thus the breakdown of proteins into free amino acids. In cachexia, there is an extensive
breakdown of muscle proteins and an increase in the production of acute phase proteins in the liver.
British Journal of Cancer (2011) 105, 1244–1251. doi:10.1038/bjc.2011.323 www.bjcancer.com
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Cachexia is characterised by anorexia, fatigue, weight loss,
decreased muscle mass and inflammation (Evans et al, 2008),
and has major effects on mortality and morbidity in cancer
patients. One-third of all cancer patients lose 450% body weight,
and it is estimated that cachexia accounts for 20% of cancer-
related deaths, presumably largely due to cardiac or respiratory
failure or complications from immobility (Fearon, 2008).
The aetiology of cancer cachexia is largely unknown. Further-
more, there is no universally accepted and validated definition of
cachexia for use in clinical practice. Weight loss and low body
mass index (BMI) have been considered the main indicators, but
criteria that identify patients with both adverse function and
prognosis are often integrated in the definitions (Fearon et al,
2006; Evans et al, 2008; Bozzetti and Mariani, 2009).
The lack of an accepted and validated definition has been a
limitation in both genetic and clinical cachexia research. Recently,
research groups have endeavoured to establish diagnostic criteria
(Fearon et al, 2006, 2011; Evans et al, 2008; Bozzetti and Mariani,
2009), resulting in a consensus article (Fearon et al, 2011) with a
proposed framework for the definition and classification of the
condition. After validation, this could aid both pathogenetical
research and clinical trial design, and facilitate the development of
practice guidelines.
At present it cannot be predicted which patients will develop
cachexia (Tan et al, 2008), but research into the treatment of
cachexia demands methods for early identification of these
patients (Muscaritoli et al, 2010). In seeking predictors either to
guide management of the condition or to identify patients at risk
of developing severe cachexia, one may consider patient char-
acteristics, tumour biology or biochemical parameters as potential
markers (Tan et al, 2008).
The seemingly unpredictable occurrence of cachexia is the
foundation for the theory that there may be genetic predisposition
to cachexia. To date, only a few studies have addressed the
association between genetic markers in candidate genes and
cachexia (Jatoi et al, 2007; Zhang et al, 2008; Deans et al, 2009).
However, a majority of these studies are small and the numbers of
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polymorphisms investigated has been limited. Studies have found
associations with cachexia and polymorphisms in IL-1-b (Jatoi
et al, 2007; Zhang et al, 2007), IL-10 (Deans et al, 2009), IL-6
(Zhang et al, 2008) and IL-8 (Bo et al, 2010) genes. A IL-10
polymorphism (rs 1800896) is observed to be associated with
cachexia in two studies; first with a410% weight loss in a Scottish
gastro-oesophageal cancer population (Deans et al, 2009), and
recently in a Chinese gastric cancer population (Sun et al, 2010).
The IL-1-b polymorphism (rs1143634) has, however, been
reported to be associated both with weight loss (Zhang et al,
2007) and with greater improvement in weight in a prospective
study (Jatoi et al, 2007) (Table 1). For all SNPs, there is a lack of
validation studies with large sample sizes in heterogeneous cancer
populations.
The possible genetic contribution to cachexia is presumably
complex and there may be multiple genetic and environmental
components contributing to susceptibility for the condition
(Hirschhorn et al, 2002). This complex pathophysiology adds to
the methodological challenges commonly encountered when
studying genetic associations. False-positive associations are
common because of multiple statistical testing, while true positives
are few because of low power from inadequate sample sizes
(Garner, 2007). A review of publications on genetic associations
with common diseases found that only 4% of the reported
associations could be confirmed in later studies (Hirschhorn et al,
2002). Other explanations for not being able to confirm genetic
associations may be variable linkage disequilibrium between the
polymorphism studied and the causal variant, the ethnic mixture
or the gene–gene/gene –environment relations specific for the
studied populations (Hirschhorn et al, 2002). Moreover, variations
in DNA do not always lead to changes in proteins, and altered
protein constitutions are not necessarily accompanied by any
clinical significance. Thus, there is a need for thorough investigations
and confirmatory studies to establish the impact of polymorphisms.
The primary research question in this study is: can the
association between cachexia and any of the nine previously
reported single-nucleotide polymorphisms’ (SNPs) be confirmed?
The two secondary research questions are: (1) is it possible to
generate new hypothesis on the pathophysiology by considering
the associations with 191 new candidate SNPs and cachexia? and
(2) is the definition established in this study consistent with known
characteristics associated with cachexia?
PATIENTS AND METHODS
Patients and study design
Between February 2004 and April 2008, 2312 cancer patients were
included in the European Pharmacogenetic Opioid Study (EPOS)
(Klepstad et al, 2011). This was a multi-centre, cross-sectional,
observational study, which included patients with cancer at
different sites, stages and with different performance status who
received opioid treatment. Patients were recruited at 17 centres in
11 different countries. Patients aged o18 years or not capable of
understanding the language used at the study centre were not
eligible.
The appropriate ethical authorities in all participating centres
approved the study protocol, and all patients gave their oral and
written informed consent.
Clinical assessment
Age, ethnicity, gender, weight, height, Karnofsky performance
status and medication during the last 24 h were recorded. Cancer
diagnosis, presence of metastases and time since the diagnosis of
cancer were registered. Body mass index (BMI) was evaluated
according to the WHO scale. Information on survival was collected
until January 2010. Patients’ subjective health at the time of
Table 1 Polymorphism attempted validated in the present study
Gene RS-number P-values
Risk
allele Patients included Phenotype
Tan et al
(2008)
SELP (selectin) rs6136 0.000492 C 775 Patients with cancer
at different sites and stages
6 Phenotypes
LEPR (leptin receptor) rs1137100 0.00821 G (1) 45% Weight loss
GHRL (ghrelin) rs42451 0.006363 T (2) 410% Weight loss
TNFRSF1A (tumour necrosis
factor receptor)
rs4149570 0.008415 T (3) 415% Weight loss
APEH (N-acylaminoacyl-peptide
hydrolase)
rs4855881 0.000854 C (4–6) The above with CRP
concentration of 410mg l – 1
APEH (N-acylaminoacyl-peptide
hydrolase)
rs2960548 0.00298 G
Postfox01a (Forkhead box,
sub-group O)
rs17446593 0.004702 G
129 SNPs were
investigated
Deans et al
(2009)
IL-10 (1082) rs1800896 0.014 G 203 Patients with
gastro-oesophagal cancer
Weight loss 410%
(80 patients)
5 SNPs were
investigated
0.019
Zhang et al
(2007)
IL-1b (+3954) rs1143634 0.018 T 214 Patients with locally
advanced gastric cancer
Weight loss 4 10%
(91 patients)
4 SNPs were
investigated
Jatoi et al
(2007)
IL-1b (+3954) rs11436344 SNPs
were investigated
0.02 T 44 Patients with metastatic
gastric and gastro-oesophagal
cancer
Phenotype is greater improvements
in weight registered every 3 week
during chemotherapy.
Abbreviations: APEH¼ acylpeptide hydrolase; CRP¼C-reactive protein; IL¼ interleukin; SNP¼ single-nucleotide polymorphism.
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inclusion was measured by the European Organisation for
Research and Treatment of Cancer Core Quality of Life
Questionnaire, the EORTC QLQ-C30 version 3.0 (Aaronson et al,
1993). In this questionnaire, the patients report symptoms for the
past week on a four-point verbal rating scale: (1) not at all, (2) a
little, (3) quite a bit and (4) very much.
The cachexia phenotype
In order to classify cachexia, the following dichotomised factors
were applied:
 BMI: o20 kg m – 2
 Karnofsky score: o80
 CRP: X10 mg l – 1
 Appetite loss: a response of little or greater on EORTC QLQ-C30
item ‘have you lacked appetite?’
Patients were divided into three groups dependent on whether they
had all four cachexia factors (severe cachexia), two or three
cachexia factors (mild cachexia) or less than two cachexia factors
(no cachexia).
Blood sampling
Blood samples were collected at the time of inclusion and stored at
80 1C before shipment to the Norwegian University of Science
and Technology (NTNU) in Trondheim, Norway for DNA
extraction and CRP analysis.
Polymorphisms for validation analysis. Literature published
before 2009 was reviewed before genotyping. This identified two
polymorphisms that had been reported to be associated with
cancer cachexia (Jatoi et al, 2007; Zhang et al, 2007; Deans et al,
2009). In addition, a study performed in parallel with this study as
a part of our group’s research on genetics and cachexia identified
seven SNPs to be associated with cachexia (personal communica-
tion Tan). These seven SNPs are based on the preliminary analyses
using a permutation test with Po0.01 to indicate significance.
Thus, a total of nine SNPs were selected to be included in the
present validation analysis. The polymorphisms to be validated are
presented in Table 1.
Polymorphisms for exploratory analysis. Before the genetic
analyses, a further 182 candidate SNPs from 99 candidate genes
were identified as having a putative impact on cachexia
pathophysiology (see Supplementary Table 1). These genes code
for pro-inflammatory cytokines, anti-inflammatory cytokines,
endocrine hormones, muscle signalling pathways, muscle protein
degradation pathways and appetite regulation. In addition, 18
candidate SNPs were chosen based on the results from gene
expression array analysis of muscle samples from cancer patients
with cachexia (Stephens et al, 2010).
Genotyping and serum analyses. Genomic DNA extraction was
performed at HUNT Biobank, Levanger, Norway. DNA was
extracted from EDTA whole blood using the Gentra Puregene
blood kit (QIAGEN Science, Germantown, MD, USA).
Genotyping was performed using the SNPlex Genotyping System
(Applied Biosystems, Foster City, CA, USA) according to the
suppliers’ dry DNA protocol. The capillary electrophoresis was
carried out with an ABI 3730 48-capillary DNA analyser (Applied
Biosystems). SNPlex signals were analysed using the Gene Mapper
version 4.0 software (Applied Biosystems), followed by manual
reading. Samples giving low signals, which could not be
discriminated from the negative controls were removed before
the analysis and treated as missing data. Genotype clustering was
performed based on the SNPlex Rules 3730 method, following
factory default settings. This method also includes quality control
where a SNP has to exceed the 80 % call rate to pass. The software
also rejects all sample wells where the well’s behaviour deviates
from the characterisation of an ideal well. Two SNPs, rs4680 and
rs1045642, which could not be analysed by the SNPlex system,
were genotyped at the HUNT Biobank. They were analysed by
using TaqMan SNP allelic discrimination by means of an ABI
7900HT. All genotyping procedures were processed without regard
of the phenotype (all genotyping processes were performed
according to Applied Biosystems).
Haemoglobin, albumin and CRP were measured by standard
clinical chemistry analytical methods.
Statistical analyses
Demographic- and disease-related factors were explored for
possible association with the cachexia groups. The factors explored
were age, gender, cancer site, time since diagnosis and presence of
metastasis. Variables such as Karnofsky status were not included
as potential explanatory factors because they may also be affected
by cachexia.
Factors were explored for association with cachexia using
ordinal logistic regression and those that were significant
(Po0.05) in univariate analyses were subsequently included in a
stepwise multivariate regression stratified by country. Significant
(Po0.05) factors from the multivariate analyses were included as
covariates in the genetic analyses.
The association between SNPs and cachexia was analysed by
ordinal logistic regression with cachexia groups as the outcome
variable. All regression analysis was stratified by country.
Analyses were also repeated without the inclusion of covariates, as
a sensitivity check. Before exploring the genetic associations, SNPs
were rejected if the genotypes were not in Hardy–Weinberg
equilibrium (HWE) (w2-test, Po0.0005) or had minor allele
frequencies (MAF) o5%. In the exploratory analysis of the 182
candidate SNPs, the patients were randomly divided into two groups
in the ratio 1 : 2. The largest group with 2 out of 3 of the patients was
used as a development sample, and the smaller group for
confirmation of significant results found in the development sample.
For the validation analyses of the nine SNPs identified in previous
studies, the initial exploratory analysis was deemed unnecessary, and
the entire sample of patients was used in the association analysis.
Three approaches were adopted to mitigate the multiplicity
issues. First, a false discovery rate (FDR) of 10% was used for
reporting the Benjamini– Hochberg (B– H) thresholds (Benjamini
and Hochberg, 1995). If a SNP is to be classified ‘significant’, its
P-value has to exceed the B–H criterion. Second, the co-dominant
genetic model was pre-specified for the primary analyses, with
other models (dominant, recessive, additive) being considered as
exploratory analyses. A recessive trait will only be expressed if the
dominant allele is not present. In a co-dominant model both alleles
are visible in the phenotype, and in an additive model the two
alleles have an enhancing effect on each other’s influence on the
phenotype. Third, interpretation of P-values was done with
caution. STATA version 11.0 was used for all analyses (StataCorp
LP, College Station, TX, USA, 2009).
The characteristics of the three cachexia groups were compared
using ANOVA for the continuous data and w2 for the categorical
data. CRP was not normally distributed and was analysed using
the non-parametric Kruskal–Wallis test. Survival and time since
diagnosis was analysed by log-rank test.
RESULTS
A total of 1797 patients with complete data on BMI, CRP, Karnofsky
performance score, genetic analyses and appetite score were
available for analyses after excluding five patients from Greece
because of their low number, 61 patients not of European descent,
400 patients because of incomplete phenotyping data, 24 patients
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because of missing blood samples and 7 patients because of no SNPs
recorded (see Figure 1). Out of the 1797 patients left for analyses,
194 patients had all 4 cachexia factors (severe cachexia), 1304
patients had two or three cachexia factors (mild cachexia) whereas
299 patients had less than two cachexia factors (no cachexia).
After applying first univariate and then multivariate ordered
regression analysis of covariates potentially associated with
cachexia, 11 variables were considered to be of prognostic
importance for grade of cachexia. Gender, time since diagnosis,
bone metastasis and several cancer diagnoses were not signifi-
cantly associated and were therefore omitted in the subsequent
genetic analyses (see Table 2).
Validation sample
Nine candidate SNPs shown in previous studies to be associated
with cachexia were assessed (Table 1). All SNPs had a MAF 45%,
and genotype frequencies did not deviate from the HWE. Sixteen
patients failed genotyping, leaving 1781 patients for final analysis.
No SNPs were significantly associated with cachexia, neither in
the co-dominant, dominant, additive nor recessive model. Table 3
presents the results of the co-dominant model. The acylpeptide
hydrolase (APEH) SNP rs 4855881 showed a trend toward
significance (P¼ 0.0199), but the P-value was still above the
B–H criterion of 0.011 that we pre-specified as denoting significance.
Enrolment
Assessed for eligibility
(n = 2312)
Excluded (n = 512 )
Missing blood sample (n = 24)
No SNPs recorded (n = 7)
Other (Greece) (n = 5)
Analysis
Exploratory sample (secondary
outcome)
Analysed (n = 1797)
Validation sample (primary outcome)
Analysed (n = 1781)
Development sample
Analysed (n = 1204)
Sample for confirmation
Analysed (n = 593)
Missing phenotype data (n = 400)
Excluded from analysis (none of the
nine SNPs were recorded) (n = 16)
Figure 1 Flowchart demonstrating enrolment and analysis samples.
Table 2 Covariates retained in the genetic association analysis
Cachexia
Odds
ratio P-value
95% Confidence
interval
Lung cancer 1.8 o0.001 1.4, 2.4
Skin cancer 2.7 0.001 1.5, 4.8
Head and neck cancer 2.7 0.000 1.6, 4.6
Pancreas cancer 5.0 0.000 2.6, 9.5
Sarcoma 2.2 0.026 1.1, 4.5
Gastrointestinal cancer 2.1 o0.001 1.5, 2.8
Female reproductive cancer 1.9 0.002 1.3, 2.8
Age 1.0 0.078 1.0, 1.0
Liver metastasis 1.3 0.055 1.0, 1.7
Other metastasis 1.7 o0.001 1.3, 2.1
Lung metastasis 1.5 0.004 1.1, 1.9
Dependent variable is three cachexia groups, based on number of cachexia factors. (1–
0, 2–3, 4). The P-values and 95% confidence interval (CI) are from multivariate analysis.
Table 3 Co-dominant model of the nine validation sample
SNP P-value (n¼ 1781) B–H criterion OR
APEH
rs4855881 0.0199 0.011 0.78
APEH
rs2960548 0.0317 0.022 0.79
Postfox01a
rs1744659 0.1368 0.033 1.19
IL-1b
rs1143634 0.2180 0.044 0.87
SELP
rs6136 0.5000 0.056 1.10
TNFrsf1a
rs4149570 0.7933 0.067 1.03
LEPR
rs1137100 0.8343 0.078 1.02
IL-10
rs1800896 0.9005 0.089 1.01
GHRL
rs42451 0.9426 0.100 1.01
Abbreviations: APEH¼ acylpeptide hydrolase; B–H¼ Benjamini –Hochberg;
IL¼ interleukin; OR¼ odds ratio; SNP¼ single-nucleotide polymorphism;
TNF¼ tumour necrosis factor.
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Exploratory sample
The 182 candidate SNPs were analysed in order to identify new
associations between cachexia and genetic polymorphisms. After
25 SNPs were excluded because of violation of HWE or for having
a MAF o5%, 157 candidate SNPs remained.
The development and confirmatory sample were well balanced
for age, BMI, Karnofsky performance status and the three cachexia
groups (data not shown).
No SNPs were significantly associated with cachexia in both the
development sample and the confirmatory sample, neither in the
co-dominant, dominant, additive nor recessive model. The five
most significant SNPs in the dominant model are presented in
Table 4. A SNP in IRS1 (rs2234931) was significantly associated
with cachexia in the exploratory analysis. (P¼ 0.000045, B–H
criterion¼ 0.00061), but was not significant (P¼ 0.29184) in the
confirmatory sample, and the odds ratio also showed an effect in
opposite direction from that in the development sample.
Patient characteristics in cachexia patients and controls
The general characteristics of the patients are presented in Table 5.
Figure 2 presents QoL parameters distributed according to number
of cachexia factors.
The group with severe cachexia had also significantly lower median
survival of 54 days whereas the mild cachexia group had a survival of
103 days and the patients with no cachexia survived for a median 304
days after inclusion. There were significant differences in fatigue and
appetite loss among the groups (Figure 2).
There was also significantly lower physical function and lower
Karnofsky score between the groups dependent on where in the
cachexia trajectory they were classified. CRP (Po0.0001), albumin
(Po0.0001) and haemoglobin (Po0.0001) were also significantly
different among the cachexia groups.
DISCUSSION
Primary and secondary aims
None of the nine SNPs previously reported to be associated with
cachexia were associated with cachexia in this study. However, two
SNPs from the APEH gene showed a trend toward significance. The
APEH gene encodes the enzyme APEH, which is postulated to be
important in the endpoint of the ubiquitin proteasome system and
thus the breakdown of proteins into free amino acids (Perrier et al,
2005). In cachexia, there is an extensive breakdown of muscle
proteins and an increase in the production of acute phase proteins in
the liver (Fearon, 2008), so this gene is of interest in cachexia
pathophysiology. In the first study, where the APEH gene was
described as significantly associated with the condition, cachexia was
classified as a spectrum. The cut-offs were o5, o10 and o15%
weight loss, with or without systemic inflammation. In all phenotypes
with elevated CRP, APEH was significantly associated with weight loss
(Po0,01), but not when the phenotype was weight loss without CRP
elevation (personal communication Tan) The phenotype applied in
this study also involves elevated CRP. This might imply that the effect
of the enzyme APEH is important during inflammation in cachexia.
In this study, the total population of 1797 patients was divided
in two groups when exploring the 157 new candidate SNPs. One
SNP was significantly associated with cachexia in the development
sample, but was not significant in the confirmation sample. Thus,
no significant associations were discovered. There is a high risk of
false-positive results in genetic association studies because of
multiple testing and low power (Garner, 2007), and the lack of
replication has been a major limitation (Pasche and Yi, 2010).
Although a few genes have been validated, many reports of genetic
associations in common diseases have proved irreproducible in
large validation studies or meta-analysis.
Third aim
Reasons for the definition. Reliable phenotyping is a critical
component in genetic association studies of complex diseases. This
challenge particularly applies to cancer cachexia where there still is
no universally accepted and validated definition, and the
pathophysiology is presumably very complex. When different
investigators propose multiple factors to define cachexia, each
factor’s ability to predict shorter survival is sometimes explored. In
order to select a population with reduced survival, weight loss and
symptoms associated with severe cachexia, we defined severe
cachexia as BMIo20 kg m – 2, anorexia, reduced Karnofsky perfor-
mance status and concomitant systemic inflammation. In several
classification systems, BMIo20 kg m – 2 has been used to distin-
guish between the cachectic and non-cachectic patients (Evans
et al, 2008; Fearon et al, 2011), and most patients with low BMI are
sarcopenic (Antoun et al, 2010). Anorexia is often not considered
mandatory in order to categorise a patient as cachectic, but the
majority do suffer some loss of appetite (Sarhill et al, 2003).
Karnofsky performance score is associated with weight loss (Blum
et al, 2011) and is one of the most powerful predictors for survival
in cancer (Maltoni et al, 2005). Lower Karnofsky score will also
incorporate the impact of cachexia on physical function. Both
weight loss and the adverse effects of cachexia such as fatigue and
performance status have been documented associated with
systemic inflammatory response (Scott et al, 2002) and CRP has
in several studies and reviews proved to be an independent marker
for survival (Maltoni et al, 2005). The most robust biomarker for
cachexia today is therefore probably elevated CRP (Tan et al, 2008)
and it is thus included in the current four-factor definition.
Table 4 Dominant model, the five most significant SNPs
SNP
P-value; development
sample (n¼ 1204) OR
B–H
criterion
P-value; sample for
confirmation (n¼593) OR
IRS1 (insulin receptor substrate)
rs2234931 0.000045 1.88 0.00061 0.29184 0.44
LITAF (lipolysaccaride-induced tumour necrosis factor-a)
rs4280262 0.013427 0.70 0.00123 0.00099 1.92
postfox01a (Forkhead box, sub-group O)
rs1744659 0.024845 1.37 0.00184 0.95283 0.99
TTC18 (tetratricopeptide repeat domain 18)
rs3812621 0.026004 0.65 0.00245 0.91230 1.03
IL-12b
rs1368439 0.031608 2.12 0.00306 0.48657 1.26
Abbreviations: B –H¼ Benjamini –Hochberg; IL¼ interleukin; OR¼ odds ratio; SNP¼ single-nucleotide polymorphism.
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Validity of the definition. A third aim of this study was to see
whether the four-factor profile for refractory cachexia was in
coherence with known clinical characteristics of the condition.
When taking into consideration the multidimensional aspects of
cachexia, the prevalence will be lower than if applying weight loss
as the sole criterion. A previous study reported that over 80% of
pancreatic cancer patients had 410% weight loss, while only 20%
of the same patients fulfilled a three factor profile of cachexia
(Fearon et al, 2006). This three factor profile, however, proved to
embrace patients with both reduced survival and function. Cancer
cachexia is a spectrum ranging from mild cachexia to severe
cachexia. A stringent cachexia definition was attempted applied in
this study in order to identify patients with severe cachexia. As
could be expected, there are rather few patients at this end of the
spectrum. In all, 11% of the included study patients had all four
cachexia factors, but the frequency of severe cachexia varied with
type of cancer (Table 3). This is in accordance with previous
studies (Bozzetti and Mariani, 2009). The three cachexia groups
that were defined had also gradually higher CRP, lower albumin
and lower haemoglobin levels. These alterations in biochemical
markers have previously been suggested as diagnostic criteria for
the cachexia (Evans et al, 2008).
Not all cancer patients who lose weight will develop severe
cachexia, but it is important to identify patients at risk in an
early phase if preventive measures or treatment is to succeed.
However, the screening of patients to undergo preventive
interventions requires markers with low false-positive rate and
high positive predictive values to avoid unnecessary psychological
or physical toll. Patients were found to have slightly more
morbidity, worse biochemical parameters and lower survival
according to whether they have no cachexia, mild cachexia or
severe cachexia. It was not possible in this cross-sectional study to
verify whether the patients with more cachexia factors had more
weight loss.
Table 5 Characteristics of the three cachexia groups
0–1 Cachexia factors (n¼299) 2–3 Cachexia factors (n¼ 1304) 4 Cachexia factors (n¼ 194) P-values
Gender
Male 153 51% 688 53% 88 45% 0.143
Female 146 49% 616 47% 106 55%
Age 61 (25–88) 63 (18–91) 62 (19–91) 0.589
Body mass index 25 (17–45) 24 (14–45) 19 (9–20) o0.0001
Department
Hospitalised 178 59% 1056 81% 170 88% o0.0001
Outpatients 121 41% 248 19% 24 12%
Survival in days (95% CI) 304 (246–362) 103 (93–114) 54 (40–68) o0.0001
Time since diagnosis in months (95% CI) 25 (18–31) 14 (12–16) 15 (12–18) o0.0001
Karnofsky performance status 80 (20–100) 60 (20–100) 50 (20–70) o0.0001
Tumour diagnosis
Urologic 20 7% 91 7% 14 7%
Lung 35 12% 239 18% 32 17%
Breast 67 22% 170 13% 21 11%
Prostate 52 17% 145 11% 11 6%
Gastrointestinal 44 15% 272 21% 54 28%
Pancreas 0 0% 26 2% 9 5%
Female reproductive organs 14 5% 109 8% 16 8%
Head and neck 13 4% 70 5% 17 9%
Haematological 21 7% 67 5% 6 3%
Unknown origin 10 3% 36 3% 4 2%
Sarcoma 6 2% 35 3% 7 4%
Skin 1 0% 30 2% 5 3%
Others 25 8% 66 5% 8 4%
Metastasisa
Liver 59 20% 319 24% 65 34%
Bone 163 55% 589 45% 68 35%
CNS 15 5% 70 5% 14 7%
Lung 49 16% 290 22% 59 30%
Other 88 29% 520 40% 105 54%
None 56 19% 211 16% 27 14%
Medication last 24 h
Chemotherapy 61 20% 186 14% 24 13% 0.023
Steroids 145 49% 634 49% 887 46% 0.764
Antibiotics 44 15% 290 22% 40 21% 0.011
Biochemical parameters (mean and 95% CI)
Hb (mmol l – 1) 11.9 (11.7–12.1) 11.4 (11.3–11.5) 10.8 (10.6–11.1) o0.0001
Albumin (g l – 1) 36 (35–37) 32 (31–32) 29 (28–30) o0.0001
CRP (g l – 1) 12 (8–16) 58 (55–61) 78 (67–86) o0.0001
Abbreviations: CI¼ confidence interval; CNS¼ central nervous system; CRP¼C-reactive protein; Hb¼ haemoglobin. All numbers are absolute numbers or medians (range) if
nothing else is indicated. aMany patients can have more than one metastasis site.
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Evaluations of the aims
This study is the most comprehensive to date exploring genetic
polymorphisms associated with cachexia. A heterogeneous cohort
of cancer patients from different European countries was
investigated in order to identify a polymorphism with high
external validity. A majority of previous studies have looked at
polymorphisms in the host within limited cancer diagnoses (Jatoi
et al, 2007; Zhang et al, 2007; Deans et al, 2009; Bo et al, 2010).
Cachexia is present in most cancer types, but prevalence and
severity varies. One could speculate that if patients are prone to or
protected from cachexia because of their genetic build-up, it would
be the same genes involved independent of cancer diagnosis.
However, there is no evidence to confirm this. The cachexia
pathophysiology and the hosts’ reaction to the tumour might prove
to be different depending on where the tumour originated.
Although we failed both to confirm previously published genetic
associations, and to identify new possible genetic associations, our
findings do not allow for ruling out genetics in cancer cachexia
pathophysiology. Although the selection of genes in this study has
a high theoretic rationale, the complexity of the human genome
suggests there may well be other genes and SNPs involved in
cachexia. Also the genetics of the tumour are likely to influence
cancer cachexia. Moreover, a Chinese research group recently
published associations with cachexia and SNPs in the IL-6 (Zhang
et al, 2008), IL-8 (Song et al, 2009) and IL-10 (Sun et al, 2010)
genes. As these associations were published after the SNPs in this
study were genotyped, they were thus not available to us for
validation. In this study, only single SNPs were explored and not
multi-SNP interactions because of the relatively limited sample size.
In addition to exploring 157 new candidate SNPs, this study is
the first performed with the primary aim to verify polymorphisms
previously reported associated with cachexia. If the genetic effect
of these nine SNPs is weak, their association with cachexia might
still be true, although not significantly reproduced in the present
cohort of cancer patients. Owing to the variation in samples of
patients, each effect size that is reported is unavoidably imprecise.
The effect of an association tends to be over – rather than
underestimated by the first group that reports it (Hirschhorn et al,
2002), and a weak effect may not be detectable in a small under-
powered sample. To establish or confirm a polymorphism with
large external validity, but with weak effect size, it is necessary to
design larger studies or use meta-analysis.
A polymorphism with a weak effect size or which is present
only in a restricted population may still be important
clinically. Such a polymorphism might give information on
pathophysiology, and may aid in developing new drugs as
cachexia is at present largely untreatable (Hirschhorn et al,
2002). In this study, only two of nine candidate SNPs
showed associations, albeit not statistically significant after
allowing for multiple testing. Both of these SNPs are from the
APEH gene. Based on the theory of weak genetic effects, it would
be of interest to do further investigations on the effect of APEH in
cachexia.
A challenge in association studies is that the effect size of the
SNPs previously published may be too small to apply to
populations moderately different from those studied. Some studies
looking at polymorphisms and cachexia have chosen 410%
weight loss as a phenotype (Deans et al, 2009). The phenotypes
might not be directly comparable since the fraction of patients
with weight loss will be much larger than the fraction of patients
who suffer from severe cachexia with its consequences on
morbidity and mortality (Fearon et al, 2006). The present
phenotype is a compound of factors that seems to describe the
condition well, but nevertheless does not say anything about the
underlying pathophysiology. Both weight loss and the present
cachexia phenotype are probably too unspecific, and both include
patients with very different pathophysiological paths, which lead to
common endpoints. Cachexia is a complex condition, and a
phenotype that attempts to include only patients that represent a
single pathophysiological path, such as sarcopenia or well-
described inflammation, may be more successful in discovering
disease contributing genes.
In summary, the objective of this study was to validate
nine SNPs previously described associated with cachexia
and to explore 157 other candidate SNPs with the potential
to be involved in the development of the condition. This
study failed to detect any significant association with any of the
SNPs analysed and cachexia, although two SNPs from the
APEH gene had a trend towards significance. Further investiga-
tions are needed in order to establish the role of APEH in cancer
cachexia.
Supplementary Information accompanies the paper on British
Journal of Cancer website (http://www.nature.com/bjc)
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